Prevention of intraventricular haemorrhage: A role for recombinant activated factor VII?

Journal of Paediatrics and Child Health

Volumn 42, Issue 6, 2006, Pages 325-331

  Robertson, Jeremy D ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Factor VIIa; Intraventricular haemorrhage; Newborn; Premature; Prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BENZENESULFONIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR 13; ETAMSYLATE; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; HEPARIN COFACTOR II; INDOMETACIN; INOSITOL; PANCURONIUM; PROTEIN C; PROTEIN S; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTIFICIAL VENTILATION; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CATHETER THROMBOSIS; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ENCEPHALOMALACIA; HEMOPHILIA; HEMOSTASIS; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; HYPERINSULINISM; HYPOTHESIS; INFECTION RISK; INTRAPARTUM CARE; KIDNEY VEIN THROMBOSIS; MICROTHROMBUS; NECROTIZING ENTEROCOLITIS; NEUROLOGIC DISEASE; NEWBORN CARE; OFF LABEL DRUG USE; PATENT DUCTUS ARTERIOSUS; PATHOGENESIS; POLYCYTHEMIA; PREMATURE LABOR; PREMATURITY; PRENATAL CARE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PUERPERIUM; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SEPSIS; SUPPLEMENTATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENTILATED PATIENT;

CEREBRAL HEMORRHAGE; FACTOR VII; HEMOSTASIS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; RECOMBINANT PROTEINS;

EID: 33744768383     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2006.00867.x     Document Type: Review

References (74)

1. Roland EH, Hill A. Germinal matrix-intraventricular hemorrhage in the premature newborn: management and outcome. Neurol. Clin. N. Am. 2003 21 : 833 51.
2. Vergani P, Patane L, Doria P et al. Risk factors for neonatal intraventricular haemorrhage in spontaneous prematurity at 32 weeks gestation or less. Placenta 2000 21 : 402 7.
3. Wells JT, Ment LR. Prevention of intraventricular hemorrhage in preterm infants. Early Hum. Dev. 1995 42 : 209 33.
4. Whitelaw A. Intraventricular haemorrhage and posthaemorrhagic hydrocephalus: pathogenesis, prevention and future interventions. Semin. Neonatol. 2001 6 : 135 46.
5. Saxonhouse MA, Sola MC. Platelet function in term and preterm neonates. Clin. Perinatol. 2004 31: 15 24.
6. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004 104: 3858 64.
7. Ment LR, Stewart WB, Ardito TA, Madri JA. Germinal matrix microvascular maturation correlates inversely with the risk period for neonatal intraventricular hemorrhage. Dev. Brain Res. 1995 84: 142 9.
8. Papile L, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 g. J. Pediatr. 1978 92: 529 34.
9. Vohr BR, Allan WC, Westerveld M et al. School-age outcomes of very low birth weight infants in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics 2003 111: e340 346.
10. de Vries LS, Rennie JM. Preterm brain injury. In: Rennie JM, Roberton NRC, eds. Textbook of Neonatology, 3rd edn. Edinburgh: Churchill Livingstone, 1999 1252 66.
11. Papile L. Intracranial hemorrhage. In: Fanaroff AA, Martin RJ, eds. Neonatal-Perinatal Medicine, Vol. 2, 7th edn. St Louis: Mosby, 2002 879 87.
12. Creasy RK. Preterm birth prevention: where are we? Am. J. Obstet. Gynecol. 1993 168: 1223 30.
13. Tucker J, McGuire W. Epidemiology of preterm birth. Br. Med. J. 2004 329: 675 8.
14. Haram K, Mortensen JHS, Wollen A. Preterm delivery: an overview. Acta Obstet. Gynecol. Scand. 2003 82: 687 704.
15. Ment LR, Oh W, Ehrenkranz RA et al. Low dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994 93: 543 50.
16. Cools F, Offringa M. Neuromuscular paralysis for newborn infants receiving mechanical ventilation. Cochrane Database Syst. Rev. 2005 2 CD002773.
17. Howlett A, Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst. Rev. 2003 4 CD000366.
18. Felderhoff-Mueser U, Buhrer C. Clinical measures to preserve cerebral integrity in preterm infants. Early Hum. Dev. 2005 81: 237 44.
19. Fish WH, Cohen MC, Franzek DF, Williams JM, Lemons JA. Effect of intramuscular vitamin E on mortality and intracranial hemorrhage in neonates of 100 grams or less. Pediatrics 1990 85: 578 84.
20. Brion LP, Bell EF, Raghuveer TS, Vitamin E. supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst. Rev. 2003 4 CD003665.
21. Setzer ES, Webb IB, Wassenaar JW, Reeder JD, Mehta PS, Eitzman DV. Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant. J. Pediatr. 1982 100: 599 605.
22. Gupta JM, Starr H, Fincher P, Lam-Po-Tang PR. Intraventricular haemorrhage in the newborn. Med. J. Aust. 1976 2: 338 40.
23. Schulte J, Osborne J, Benson JWT et al. Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial. Arch. Dis. Child. Fetal Neonatal Ed. 2005 90: F31 F35.
24. Elbourne D, Ayers S, Dellagrammaticas H, Johnson A, Leloup M, Lenoir-Piat S. Randomised controlled trial of prophylactic etamsylate: follow-up at 2 years of age. Arch. Dis. Child. Fetal Neonatal Ed. 2001 84: F183 F187.
25. Andrew M, Vegh P, Caco C. A randomized controlled trial of platelet transfusions in thrombocytopenic premature infants. J. Pediatr. 1993 123: 285 91.
26. Shirahata A, Nakamura T, Shimono M, Kaneko M, Tanaka S. Blood coagulation findings and the efficacy of factor XIII concentrate in premature infants with intracranial hemorrhages. Thromb. Res. 1990 57: 755 63.
27. Waltl H, Fodisch HJ, Kurz R, Hohenauer L, Mitterstieler G, Rossler H. Intracranial haemorrhage in low birth weight infants and prophylactic administration of coagulation-factor concentrate. Lancet 1973 1: 1284 6.
28. Turner T, Prowse CV, Prescott RJ, Cash JD. A clinical trial on the early detection and correction of haemostatic defects in selected high-risk neonates. Br. J. Haematol. 1981 47: 65 75.
29. Van de Bor M, Briet E, Van Bel F, Ruys JH. Hemostasis and periventricular-intraventricular hemorrhage of the newborn. Am. J. Dis. Child. 1986 140: 1131 4.
30. Aitken MG. Recombinant factor VIIa. Emerg. Med. Aust. 2004 16: 446 55.
31. Ghorashian S, Hunt BJ. Off-license use of recombinant activated factor VII. Blood Rev. 2004 18: 245 59.
32. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003 17: S1 S5.
33. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr. Med. Chem. 2003 10: 797 811.
34. Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in 'acquired' hemophilia. Arterioscler. Thromb. Vasc. Biol. 2003 23: 123 9.
35. Lloyd JV, Joist JH. rVIIa: a universal hemostatic agent? Curr. Hem. Rep. 2002 1: 19 26.
36. Monroe DM, Roberts HR. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler. Thromb. Vasc. Biol. 2003 23: 8 9.
37. Uhlmann EJ, Eby CS. Recombinant activated factor VII for non-haemophiliac bleeding patients. Curr. Opin. Hematol. 2004 11: 198 204.
38. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J. Thromb. Haemost. 2004 2: 899 909.
39. Fattorutto M, Tourreau-Pham S, Mazoyer E et al. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits. Can. J. Anaesth. 2004 51: 672 9.
40. Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb. Haemost. 2004 91: 977 85.
41. Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics: a systematic review. Thromb. Haemost. 2004 92: 738 46.
42. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit. Care. Med. 2005 33: 883 90.
43. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral haemorrhage. N. Engl. J. Med. 2005 352: 777 85.
44. Laffan M, O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy D, Smith OP. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul. Fibrinolysis 2003 14 Suppl. 1 S35 S38.
45. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am. J. Pediatr. Hematol. Oncol. 1990 12: 95 104.
46. Andrew M. The relevance of developmental hemostasis to hemorrhagic disorders of newborns. Semin. Perinatol. 1997 21: 70 85.
47. Caccamo ML, Rossi E, Salmoiraghi MG, Mondonico P, Gianotti GA, Marini A. The fibrinolytic system in the newborn: role of histidine-rich glycoprotein. Biol. Neonate. 1992 61: 281 4.
48. Greenway A, Massicotte MP, Monagle P. Neonatal thrombosis and its treatment. Blood Rev. 2004 18: 75 84.
49. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb. Haemost. 1992 68: 325 30.
50. Corrigan JJ. Neonatal thrombosis and the thrombolytic system: pathophysiology and therapy. Am. J. Pediatr. Hematol. Oncol. 1988 10: 83 91.
51. Corrigan JJ Sleeth JJ, Jeter M, Lox CD. Newborn's fibrinolytic mechanism: components and plasmin generation. Am. J. Hematol. 1989 32: 273 8.
52. Streif W, Paes B, Berry L, Andrew M, Andreasen RB, Chan AKC. Influence of exogenous factor VIIa on thrombin generation in cord plasma of full-term and pre-term newborns. Blood Coagul. Fibrinolysis 2000 11: 349 57.
53. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul. Fibrinolysis 2003 14: 117 20.
54. Pychynska-Pokorska M, Moll JJ, Krajewski W, Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr. Crit. Care. Med. 2004 5: 297 8.
55. Brown JB, Emerick KM, Brown DL, Whitington PF, Alonso EM. Recombinant factor VIIa improves coagulopathy caused by liver failure. J. Pediatr. Gastroenterol. Nutr. 2003 37: 268 72.
56. Young G, Nugent DJ. Prevention of bleeding complications in neonates with liver failure undergoing surgery using recombinant factor VIIa. Hematology 2001 6: 341 6.
57. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr. Crit. Care Med. 2005 6: 473 6.
58. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J. Perinatol. 2002 22: 672 4.
59. Fontaine MJ, Lazarchick J, Taylor S, Annibale D. Use of recombinant factor VIIa in infants with severe coagulopathy. J. Perinatol. 2004 24: 310 11.
60. Veldman A, Fischer D, Voigt B, Schlosser R, Allendorf A, Kreuz W. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002 28: 1635 7.
61. Mariani G, Testa MG, Di Paolantino T, Bech RM, Hedner U et al. Use of rVIIa in treatment of congenital factor VII deficiency. Vox Sang. 1999 77: 131 6.
62. Chuansumrit A, Nuntnarumit P, Okascharoen C, Teeraratkul S, Suwansingh S, Supapannachart S. The use of recombinant factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics 2002 100: 169 71.
63. Chuansumrit A, Puapunwattana S, Rasmidat P et al. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency. J. Med. Assoc. Thai. 2002 85 Suppl. 4 S1059 S1064.
64. Velik-Salchner C, Sergi C, Fries D, Moser P, Streif W, Kolbitsch C. Use of recombinant factor VIIa in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth. Analg. 2005 101: 920 9.
65. Wong W, Huang WC, Miller R, McGinty K, Whisnant JK. Clinical efficacy and recovery levels of recombinant factor VIIa in the treatment of intracranial haemorrhage in severe neonatal factor VII deficiency. Haemophilia 2000 6: 50 4.
66. Girisch M, Rauch R, Carbon R, Habash T, Hofbeck M. Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa. Eur. J. Pediatr. 2004 163: 118 19.
67. Tokunaga C, Hiramatsu Y, Horigome H, Takahashi-Igari M, Noma M, Sakakibara Y. Palliative open heart surgery in an infant with factor VII deficiency. Ann. Thorac. Surg. 2003 76: 2093 4.
68. Mathew P, Winter SS, Frost JD, Hanrahan J, Schwartz M, Jones JE. Novel applications of recombinant factor VIIa for management of pediatric coagulopathic diseases. J. Pediatr. Hematol. Oncol. 2003 25: 499 502.
69. Millar CG, Stringer MD, Sugarman I, Richards M. The use of rVIIa for bleeding in paediatric practice. Haemophilia 2005 11: 171 4.
70. Razon Y, Erez E, Vidne B et al. Recombinant factor VIIs as a hemostatic agent after surgery for congenital heart disease. Paediatr. Anaesth. 2005 15: 235 40.
71. Tancabelic J, Haun SE. Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus type 7. Pediatr. Blood Cancer. 2004 43: 170 6.
72. Verrijckt A, Proulx F, Morneau S, Vorbecky S. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J. Thorac. Cardiovasc. Surg. 2004 127: 1812 13.
73. Andrew ME, Monagle P, deVeber G, Chan AK. Thromboembolic disease and antithrombotic therapy in newborns. Hematology 2001 358 74.
74. Schmidt B. The etiology, diagnosis and treatment of thrombotic disorders in newborn infants: a call for international and multi-institutional studies. Semin. Perinatol. 1997 21: 86 9.